Faculty Opinions recommendation of Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

Author(s):  
Robert Keith ◽  
Melissa New
PLoS Medicine ◽  
2017 ◽  
Vol 14 (4) ◽  
pp. e1002277 ◽  
Author(s):  
Kevin ten Haaf ◽  
Jihyoun Jeon ◽  
Martin C. Tammemägi ◽  
Summer S. Han ◽  
Chung Yin Kong ◽  
...  

PLoS Medicine ◽  
2020 ◽  
Vol 17 (9) ◽  
pp. e1003403
Author(s):  
Kevin ten Haaf ◽  
Jihyoun Jeon ◽  
Martin C. Tammemägi ◽  
Summer S. Han ◽  
Chung Yin Kong ◽  
...  

2019 ◽  
Vol 112 (5) ◽  
pp. 466-479 ◽  
Author(s):  
Kevin ten Haaf ◽  
Mehrad Bastani ◽  
Pianpian Cao ◽  
Jihyoun Jeon ◽  
Iakovos Toumazis ◽  
...  

Abstract Background Risk-prediction models have been proposed to select individuals for lung cancer screening. However, their long-term effects are uncertain. This study evaluates long-term benefits and harms of risk-based screening compared with current United States Preventive Services Task Force (USPSTF) recommendations. Methods Four independent natural history models were used to perform a comparative modeling study evaluating long-term benefits and harms of selecting individuals for lung cancer screening through risk-prediction models. In total, 363 risk-based screening strategies varying by screening starting and stopping age, risk-prediction model used for eligibility (Bach, PLCOm2012, or Lung Cancer Death Risk Assessment Tool [LCDRAT]), and risk threshold were evaluated for a 1950 US birth cohort. Among the evaluated outcomes were percentage of individuals ever screened, screens required, lung cancer deaths averted, life-years gained, and overdiagnosis. Results Risk-based screening strategies requiring similar screens among individuals ages 55–80 years as the USPSTF criteria (corresponding risk thresholds: Bach = 2.8%; PLCOm2012 = 1.7%; LCDRAT = 1.7%) averted considerably more lung cancer deaths (Bach = 693; PLCOm2012 = 698; LCDRAT = 696; USPSTF = 613). However, life-years gained were only modestly higher (Bach = 8660; PLCOm2012 = 8862; LCDRAT = 8631; USPSTF = 8590), and risk-based strategies had more overdiagnosed cases (Bach = 149; PLCOm2012 = 147; LCDRAT = 150; USPSTF = 115). Sensitivity analyses suggest excluding individuals with limited life expectancies (<5 years) from screening retains the life-years gained by risk-based screening, while reducing overdiagnosis by more than 65.3%. Conclusions Risk-based lung cancer screening strategies prevent considerably more lung cancer deaths than current recommendations do. However, they yield modest additional life-years and increased overdiagnosis because of predominantly selecting older individuals. Efficient implementation of risk-based lung cancer screening requires careful consideration of life expectancy for determining optimal individual stopping ages.


2017 ◽  
Vol 4 (4) ◽  
pp. 307-320 ◽  
Author(s):  
Lori C. Sakoda ◽  
Louise M. Henderson ◽  
Tanner J. Caverly ◽  
Karen J. Wernli ◽  
Hormuzd A. Katki

2021 ◽  
Vol 10 (2) ◽  
pp. 1083-1090
Author(s):  
Marcin Ostrowski ◽  
Franciszek Bińczyk ◽  
Tomasz Marjański ◽  
Robert Dziedzic ◽  
Sylwia Pisiak ◽  
...  

2020 ◽  
Vol 7 (1) ◽  
pp. e000811
Author(s):  
Oluf Dimitri Røe

Screening a population for a potentially deadly disease, the ultimate goal must be to prevent morbidity and mortality from this disease for the whole population. Unlike breast cancer or cervical cancer screening, where all women are screened after a certain age, CT screening for lung cancer has been based on selection of putative high-risk individuals based on age and smoking cut-off values. The type of selection used leaves too many high-risk individuals behind. The solution is to use only validated risk prediction models for selection.


Sign in / Sign up

Export Citation Format

Share Document